Health Care & Life Sciences » Pharmaceuticals | HanAll Biopharma Co. Ltd.

HanAll Biopharma Co. Ltd. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
74,228
80,880
80,023
82,882
84,231
91,839
Cost of Goods Sold (COGS) incl. D&A
43,058
41,681
44,274
45,388
42,467
43,564
Gross Income
31,171
39,199
35,749
37,493
41,763
48,275
SG&A Expense
43,392
37,743
39,360
36,577
37,637
42,221
EBIT
12,983
815
4,280
285
3,540
5,474
Unusual Expense
7,892
13,864
111
279
2,441
4,473
Non Operating Income/Expense
818
951
273
592
630
1,075
Interest Expense
1,374
989
680
-
-
-
Pretax Income
20,580
12,757
4,825
1,674
2,627
3,996
Income Tax
919
99
2,252
352
3,187
696
Consolidated Net Income
21,499
12,658
7,077
2,026
5,813
3,300
Net Income
21,499
12,658
7,077
2,026
5,813
3,300
Net Income After Extraordinaries
21,499
12,658
7,077
2,026
5,813
3,300
Net Income Available to Common
21,499
12,658
7,077
2,026
5,813
3,300
EPS (Basic)
529.00
314.00
159.00
40.00
114.00
64
Basic Shares Outstanding
41
40
44
51
51
51
EPS (Diluted)
528.73
314.42
159.47
39.98
113.73
64.48
Diluted Shares Outstanding
41
40
44
51
51
51
EBITDA
11,031
3,075
1,963
2,520
5,702
7,463
Other Operating Expense
762
641
668
630
587
581
Non-Operating Interest Income
851
330
519
1,075
898
1,921

About HanAll Biopharma Co.

View Profile
Address
43 Sangseodang 1-gil
Daejeon DE 34344
Korea, Republic Of
Employees -
Website http://www.hanall.co.kr
Updated 07/08/2019
HANALL BIOPHARMA Co., Ltd. engages in the manufacture and sale of synthetic drug and biopharmaceutical. Its products include medicine for digesting, high blood pressure, cerebrovascular disease, myocardial infarction, anti-diabetics, antibiotics, gastrointestinal, bone structure, erectile dysfunction, hives and other pharmaceutical products. The company was founded by Byeong-Tae Kim on November 20, 1973 and is headquartered in Daejeon, South Korea.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.